Figure 2
Expression of FcγRII/CD32 on B cells from ITP patients before and after therapy and from healthy controls. (A) Representative scattergrams of surface expression of FcγRII/CD32 on CD19+ B cells from a healthy control and an ITP patient before HD-DXM therapy. CD19+ B cells were gated based on their forward/side scatter. (B) Expression of FcγRII/CD32 (MFI) on B cells from ITP patients before and after HD-DXM therapy and from healthy controls.

Expression of FcγRII/CD32 on B cells from ITP patients before and after therapy and from healthy controls. (A) Representative scattergrams of surface expression of FcγRII/CD32 on CD19+ B cells from a healthy control and an ITP patient before HD-DXM therapy. CD19+ B cells were gated based on their forward/side scatter. (B) Expression of FcγRII/CD32 (MFI) on B cells from ITP patients before and after HD-DXM therapy and from healthy controls.

Close Modal

or Create an Account

Close Modal
Close Modal